Indegene (NSEI:INDGN) - Stock Price, News & Analysis

INDGN Stock Overview

Operates as a life sciences commercialization company in India, the United States, Europe, and internationally.

INDGN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	6/6
Financial Health	5/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (44.5x) is below the Life Sciences industry average (49.7x)

Earnings are forecast to grow 17.36% per year

Earnings grew by 43.2% over the past year

Risk Analysis

No risks detected for INDGN from our risk checks.

Indegene Limited Competitors

Akums Drugs and Pharmaceuticals

NSEI:AKUMS

₹134.0b

Syngene International

NSEI:SYNGENE

₹365.1b

Innova Captab

NSEI:INNOVACAP

₹45.5b

Tarsons Products

NSEI:TARSONS

₹25.5b

Price History & Performance

Summary of all time highs, changes and price drops for Indegene
Historical stock prices
Current Share Price	₹662.30
52 Week High	₹726.50
52 Week Low	₹470.10
Beta	0
11 Month Change	16.44%
3 Month Change	16.57%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	46.53%

Recent updates

Shareholder Returns

	INDGN	IN Life Sciences	IN Market
7D	-2.4%	-1.3%	0.4%
1Y	n/a	39.5%	43.9%

Return vs Industry: Insufficient data to determine how INDGN performed against the Indian Life Sciences industry.

Return vs Market: Insufficient data to determine how INDGN performed against the Indian Market.

Price Volatility

Is INDGN's price volatile compared to industry and market?
INDGN volatility
INDGN Average Weekly Movement	5.4%
Life Sciences Industry Average Movement	6.4%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	3.8%

Stable Share Price: INDGN has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine INDGN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	4,367	Manish Gupta	www.indegene.com

Indegene Limited operates as a life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies.

Indegene Limited Fundamentals Summary

How do Indegene's earnings and revenue compare to its market cap?
INDGN fundamental statistics
Market cap	₹158.47b
Earnings (TTM)	₹3.56b
Revenue (TTM)	₹26.59b

44.5x

P/E Ratio

6.0x

P/S Ratio

Is INDGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INDGN income statement (TTM)
Revenue	₹26.59b
Cost of Revenue	₹0
Gross Profit	₹26.59b
Other Expenses	₹23.03b
Earnings	₹3.56b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	14.88
Gross Margin	100.00%
Net Profit Margin	13.39%
Debt/Equity Ratio	34.3%

How did INDGN perform over the long term?

See historical performance and comparison

Indegene NSEI:INDGN Stock Report